PEGBIO CO-B (02565) Rises Nearly 5% Again as Paidakang Successfully Included in National Medical Insurance, With Accelerated Volume Growth Expected Ahead

Stock News11-17

PEGBIO CO-B (02565) rose nearly 5% again. As of press time, it was up 3.57% at HK$3.335, with a turnover of HK$21.5625 million.

On the news front, the company's core product Paidakang® (Beinaglutide Injection) has been successfully included in the 2026 National Medical Insurance Drug Catalog, marking a major commercial milestone. Previously, PEGBIO entered into an exclusive commercialization partnership in mainland China with Shanghai Tengrui Pharmaceutical, setting a target of cumulative sales exceeding RMB 10 billion, with product sales revenue to be recognized by PEGBIO.

Public information shows that Paidakang is a once-weekly GLP-1 formulation used for blood glucose control in adults with type 2 diabetes. The company stated that Paidakang is the group's first approved innovative drug product, and its inclusion in the National Medical Insurance Catalog is expected to improve patient affordability and medication accessibility, which will help drive product admission, clinical promotion, and market coverage across medical institutions nationwide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment